Allergan-KYTHERA Deal Gets U.S. Antitrust Approval

(RTTNews) - Allergan plc (AGN) and KYTHERA Biopharmaceuticals Inc. (KYTH) announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Allergan's pending acquisition of KYTHERA.

The early termination of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions, including receipt of approval by KYTHERA's stockholders.

In June, Botox maker Allergan agreed to acquire Kythera Biopharmaceuticals Inc. for about $2.1 billion in cash and stock.